Pharma Videos
Pharma Videos
Pharma Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Therapy resistance remains a major hurdle in prostate cancer, especially after initial success with hormone‑based treatments. The Deng Lab at Yale School of Medicine is dedicated to uncovering the molecular mechanisms that enable cancer cells to evade therapy. The team combines patient‑derived genomic data with artificial‑intelligence algorithms to pinpoint mutations that drive resistance. These computational hits are then tested in patient‑derived tissue cultures, providing a translational bridge from data to biology. Lab leader Dr. Deng cites a personal motivation—watching a friend battle leukemia—as a driving force, emphasizing the lab’s patient‑centered mission to develop drugs that degrade resistance‑promoting proteins and to create predictive biomarkers. If successful, these efforts could yield combination regimens that preempt resistance, offering clinicians tools to personalize treatment and improve long‑term survival for prostate cancer patients.
Eli Lilly is quietly reshaping its R&D agenda, moving from a narrow GLP‑1 obesity play toward a broader longevity strategy. The company’s recent moves signal an ambition to become a “big farmer” of age‑related therapeutics, even if the term does not...
The United States is considering a 100% tariff on certain patented pharmaceutical products, a move that could strip Taiwan’s drugs of preferential market treatment. Darson Chiu, director of the Confederation of Asia‑Pacific Chambers of Commerce and Industry, warned that the...
The video reports that President Donald Trump signed an executive order imposing a 100% tariff on imported patented medicines, citing a national‑security risk after an investigation found that 53% of such drugs in the United States are sourced abroad. The...
The round‑table focused on rising concerns that the Trump administration could levy up to 100% tariffs on imported branded and patented medicines, a move that would directly affect Indian pharmaceutical exporters. Traders reacted by pushing the India pharma index down...
Life Sciences Today host Danny Lieberman interviews Zena Sarif, founder of Yandu, about the chronic inefficiencies that prolong clinical‑trial timelines and how her startup aims to streamline the process. Sarif explains that up to 12‑18 months of a drug’s development are...
The RISE Together Session 3.1 convened experts to explore data‑sharing strategies across the rare‑disease ecosystem, using amyotrophic lateral sclerosis (ALS) as a pilot. Panelists Colin Hovinga of the Critical Path Institute and Natanya Kerper of the Cystic Fibrosis Foundation highlighted...
In a special edition of FDA Direct, the agency’s leadership reviewed a year of restructuring, record‑setting approvals, and a forward‑looking agenda focused on speed, safety and affordability. The discussion highlighted a near‑record 67 new drug approvals, an average review time...
The video focuses on Bio4’s phased, risk‑based strategy for addressing particulate contamination in cell and gene therapy (CGT) raw and starting materials, a gap that has long plagued the industry. Bio4 is assembling a subgroup to draft best‑practice guidance, potentially...
The Rare Disease Day 2026 session titled “Gene Therapy in Practice” highlighted Johns Hopkins’ emerging program to deliver gene‑based treatments for pediatric neuromuscular disorders. Speakers—Dr. Jessica Nance, nurse practitioner Maria Belellios, and pharmacy coordinator Danielle Pennock—outlined the institution’s clinical‑trial legacy,...
Poolbeg Pharma used the briefing to detail its strategic roadmap, focusing on two parallel tracks – expanding its intellectual‑property holdings worldwide and advancing a pivotal clinical study in relapsed‑refractory multiple myeloma. The company said it will tap the Patent Prosecution Highway...
The webinar examined the Inflation Reduction Act’s new Medicare drug‑price negotiation program, focusing on the Centers for Medicare & Medicaid Services’ (CMS) recently published explanations for the 2027 maximum fair prices (MFPs). These explanations, released before the March 1 deadline, detail...
Poolbeg Pharma announced that IP Australia has issued a formal certificate of grant for its patent covering the use of any P38 MAPK inhibitor, including its lead oral candidate pod001, to prevent cancer‑immunotherapy‑induced cytokine release syndrome (CRS). The approval...
The video features Dr. Glaucomflecken discussing a new oral PCSK9 inhibitor, Enlisticide, and its recent New England Journal of Medicine publication. The drug targets patients with familial hypercholesterolemia or elevated LDL—specifically those with prior cardiovascular events (LDL > 55 mg/dL) or at high...
The video outlines an early‑engagement checklist for Commissioning, Qualification and Validation (CQV) that begins at the Basis of Design (BOD) and continues through due‑diligence activities. It explains why most issues surface during the CNQ phase—earlier decisions funnel problems downstream—and introduces a...
